Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

725 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia.
Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. Short NJ, et al. Among authors: konopleva m. Am J Hematol. 2016 Jun;91(4):385-9. doi: 10.1002/ajh.24296. Epub 2016 Feb 9. Am J Hematol. 2016. PMID: 26800008 Free PMC article.
Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM. Weiser MA, et al. Among authors: konopleva m. Cancer. 2004 Mar 15;100(6):1179-85. doi: 10.1002/cncr.20071. Cancer. 2004. PMID: 15022284 Free article.
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Kojima K, et al. Among authors: konopleva m. Blood. 2006 Aug 1;108(3):993-1000. doi: 10.1182/blood-2005-12-5148. Epub 2006 Mar 16. Blood. 2006. PMID: 16543464 Free PMC article.
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ. Yee KW, et al. Among authors: konopleva m. Clin Cancer Res. 2006 Sep 1;12(17):5165-73. doi: 10.1158/1078-0432.CCR-06-0764. Clin Cancer Res. 2006. PMID: 16951235 Clinical Trial.
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M. Zhang W, et al. Among authors: konopleva m. J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29. J Natl Cancer Inst. 2008. PMID: 18230792 Clinical Trial.
725 results